ANN ARBOR -- AlphaCore Pharma announced Tuesday that results from the company's Phase 1 clinical trial have met the primary endpoint by demonstrating the safety and tolerability of the drug ACP-501 ...
AlphaCore Pharma, announced today that results from the company’s Phase 1 clinical trial have met the primary endpoint by demonstrating the safety and tolerability of the drug ACP-501 (recombinant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback